Induction of Humoral and Cellular Immune Responses Against the HIV-1 Envelope Protein Using γ-retroviral Virus-like Particles

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2011 Aug 3

PMID 21806819

Citations 3

Authors

Tea Kirkegaard

Adam Wheatley

Jesper Melchjorsen

Shervin Bahrami

Finn S Pedersen

Robert J Center

Damian F J Purcell

Lars Ostergaard

Mogens Duch

Martin Tolstrup

Affiliations

Soon will be listed here.

Abstract

This study evaluates the immunogenicity of the HIV envelope protein (env) in mice presented either attached to γ-retroviral virus-like-particles (VLPs), associated with cell-derived microsomes or as solubilized recombinant protein (gp160). The magnitude and polyfunctionality of the cellular immune response was enhanced when delivering HIV env in the VLP or microsome form compared to recombinant gp160. Humoral responses measured by antibody titres were comparable across the groups and low levels of antibody neutralization were observed. Lastly, we identified stronger IgG2a class switching in the two particle-delivered antigen vaccinations modalities compared to recombinant gp160.

Citing Articles

Characterization of HIV-1 infection and innate sensing in different types of primary human monocyte-derived macrophages.

Diget E, Zuwala K, Berg R, Laursen R, Soby S, Ostergaard L Mediators Inflamm. 2013; 2013:208412.

PMID: 23431237 PMC: 3569920. DOI: 10.1155/2013/208412.

Immune responses in mice vaccinated with virus-like particles composed of the GP5 and M proteins of porcine reproductive and respiratory syndrome virus.

Nam H, Chae K, Song Y, Lee N, Lee J, Park S Arch Virol. 2013; 158(6):1275-85.

PMID: 23392631 PMC: 4126520. DOI: 10.1007/s00705-013-1612-z.

Abrogation of contaminating RNA activity in HIV-1 Gag VLPs.

Valley-Omar Z, Meyers A, Shephard E, Williamson A, Rybicki E Virol J. 2011; 8:462.

PMID: 21975161 PMC: 3204299. DOI: 10.1186/1743-422X-8-462.

References

Tolstrup M, Selzer-Plon J, Laursen A, Bertelsen L, Gerstoft J, Duch M . Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K). AIDS. 2007; 21(4):519-21. DOI: 10.1097/QAD.0b013e3280187558. View

Quan F, Sailaja G, Skountzou I, Huang C, Vzorov A, Compans R . Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins. Vaccine. 2007; 25(19):3841-50. PMC: 1973151. DOI: 10.1016/j.vaccine.2007.01.107. View

Buonaguro L, Visciano M, Tornesello M, Tagliamonte M, Biryahwaho B, Buonaguro F . Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol. 2005; 79(11):7059-67. PMC: 1112107. DOI: 10.1128/JVI.79.11.7059-7067.2005. View

Leclerc C, Deriaud E, Rojas M, Whalen R . The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell Immunol. 1997; 179(2):97-106. DOI: 10.1006/cimm.1997.1161. View

Bellier B, Huret C, Miyalou M, Desjardins D, Frenkiel M, Despres P . DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine. 2009; 27(42):5772-80. DOI: 10.1016/j.vaccine.2009.07.059. View

Morita S, Kojima T, Kitamura T . Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 2000; 7(12):1063-6. DOI: 10.1038/sj.gt.3301206. View

Hammonds J, Chen X, Fouts T, DeVico A, Montefiori D, Spearman P . Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J Virol. 2005; 79(23):14804-14. PMC: 1287556. DOI: 10.1128/JVI.79.23.14804-14814.2005. View

Montefiori D, Mascola J . Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?. Curr Opin HIV AIDS. 2010; 4(5):347-51. PMC: 2879149. DOI: 10.1097/COH.0b013e32832f4a4d. View

Devitt G, Emerson V, Holtkotte D, Pfeiffer T, Pisch T, Bosch V . Incorporation of chimeric HIV-SIV-Env and modified HIV-Env proteins into HIV pseudovirions. Virology. 2007; 361(2):465-71. DOI: 10.1016/j.virol.2006.11.029. View

10.

Kalyanaraman V, Rodriguez V, Veronese F, Rahman R, Lusso P, Devico A . Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 1990; 6(3):371-80. DOI: 10.1089/aid.1990.6.371. View

11.

Center R, Wheatley A, Campbell S, Gaeguta A, Peut V, Alcantara S . Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine. 2009; 27(47):6605-12. DOI: 10.1016/j.vaccine.2009.08.016. View

12.

Schnierle B, Stitz J, Bosch V, Nocken F, Engelstadter M, Kurth R . Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci U S A. 1997; 94(16):8640-5. PMC: 23056. DOI: 10.1073/pnas.94.16.8640. View

13.

Mammano F, Salvatori F, Indraccolo S, De Rossi A, Chieco-Bianchi L, Gottlinger H . Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus particles and gene transfer into CD4+ cells. J Virol. 1997; 71(4):3341-5. PMC: 191476. DOI: 10.1128/JVI.71.4.3341-3345.1997. View

14.

Hoxie J . Toward an antibody-based HIV-1 vaccine. Annu Rev Med. 2009; 61:135-52. DOI: 10.1146/annurev.med.60.042507.164323. View

15.

Cantin R, Diou J, Belanger D, Tremblay A, Gilbert C . Discrimination between exosomes and HIV-1: purification of both vesicles from cell-free supernatants. J Immunol Methods. 2008; 338(1-2):21-30. DOI: 10.1016/j.jim.2008.07.007. View

16.

Byland R, Vance P, Hoxie J, Marsh M . A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein. Mol Biol Cell. 2006; 18(2):414-25. PMC: 1783771. DOI: 10.1091/mbc.e06-06-0535. View

17.

Johnson P, Schnepp B, Zhang J, Connell M, Greene S, Yuste E . Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med. 2009; 15(8):901-6. PMC: 2723177. DOI: 10.1038/nm.1967. View

18.

Mascola J, Stiegler G, Vancott T, Katinger H, Carpenter C, Hanson C . Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000; 6(2):207-10. DOI: 10.1038/72318. View

19.

Crooks E, Moore P, Franti M, Cayanan C, Zhu P, Jiang P . A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology. 2007; 366(2):245-62. PMC: 2080857. DOI: 10.1016/j.virol.2007.04.033. View

20.

Zhu P, Liu J, Bess Jr J, Chertova E, Lifson J, Grise H . Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature. 2006; 441(7095):847-52. DOI: 10.1038/nature04817. View